Thrivent Financial for Lutherans’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.91M Sell
77,119
-2,270
-3% -$54.1K ﹤0.01% 1498
2025
Q4
$1.85M Sell
79,389
-3,610
-4% -$80.4K ﹤0.01% 1543
2025
Q3
$1.64M Sell
82,999
-1,310
-2% -$26.9K ﹤0.01% 1465
2025
Q2
$1.83M Buy
84,309
+1,957
+2% +$46.2K ﹤0.01% 1412
2025
Q1
$2M Sell
82,352
-4,308
-5% -$97K ﹤0.01% 1291
2024
Q4
$1.81M Sell
86,660
-952
-1% -$20.5K ﹤0.01% 1506
2024
Q3
$1.74M Sell
87,612
-5,538
-6% -$103K ﹤0.01% 1539
2024
Q2
$1.44M Sell
93,150
-3,740
-4% -$58.2K ﹤0.01% 1615
2024
Q1
$1.54M Buy
96,890
+7,591
+9% +$114K ﹤0.01% 1607
2023
Q4
$1.5M Sell
89,299
-2,353
-3% -$32.2K ﹤0.01% 1581
2023
Q3
$1.07M Sell
91,652
-1,618
-2% -$21.6K ﹤0.01% 1694
2023
Q2
$1.25M Sell
93,270
-1,615
-2% -$23.2K ﹤0.01% 1656
2023
Q1
$1.57M Sell
94,885
-3,326
-3% -$54.9K ﹤0.01% 1466
2022
Q4
$1.83M Buy
98,211
+427
+0.4% +$6.57K ﹤0.01% 1312
2022
Q3
$1.25M Buy
+97,784
New +$1.16M ﹤0.01% 1523

Other funds holding CPRX

Thrivent Financial for Lutherans's CPRX Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Catalyst Pharmaceutical (CPRX) stake by 2.9% in Q1 2026, selling an estimated $54.1K and leaving 77,119 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

Thrivent Financial for Lutherans first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $2M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Thrivent Financial for Lutherans held 77,119 shares of Catalyst Pharmaceutical worth $1.91M as of Q1 2026.
  • Thrivent Financial for Lutherans sold 2,270 Catalyst Pharmaceutical shares in Q1 2026, an estimated $54.1K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1498 holding.
  • Thrivent Financial for Lutherans first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • Thrivent Financial for Lutherans's Catalyst Pharmaceutical position peaked at $2M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.